A detailed history of Centaurus Financial, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Centaurus Financial, Inc. holds 10,836 shares of BMY stock, worth $438,316. This represents 0.04% of its overall portfolio holdings.

Number of Shares
10,836
Previous 12,024 9.88%
Holding current value
$438,316
Previous $616,000 4.71%
% of portfolio
0.04%
Previous 0.05%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$47.98 - $54.4 $57,000 - $64,627
-1,188 Reduced 9.88%
10,836 $587,000
Q4 2023

Feb 26, 2024

SELL
$48.48 - $57.85 $29,330 - $34,999
-605 Reduced 4.79%
12,024 $616,000
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $1,389 - $1,553
24 Added 0.19%
12,629 $733,000
Q2 2023

Aug 15, 2023

SELL
$63.71 - $70.74 $373,149 - $414,324
-5,857 Reduced 31.72%
12,605 $806,000
Q1 2023

May 17, 2023

BUY
$65.71 - $74.53 $53,619 - $60,816
816 Added 4.62%
18,462 $1.28 Million
Q4 2022

Feb 10, 2023

BUY
$68.48 - $81.09 $6,711 - $7,946
98 Added 0.56%
17,646 $1.27 Million
Q3 2022

Dec 05, 2022

SELL
$0.13 - $76.84 $6 - $3,995
-52 Reduced 0.3%
17,548 $1.25 Million
Q2 2022

Aug 02, 2022

SELL
$72.62 - $79.98 $202,391 - $222,904
-2,787 Reduced 13.67%
17,600 $1.36 Million
Q1 2022

May 13, 2022

SELL
$61.48 - $73.72 $171,590 - $205,752
-2,791 Reduced 12.04%
20,387 $1.49 Million
Q4 2021

Feb 01, 2022

BUY
$53.63 - $62.52 $56,418 - $65,771
1,052 Added 4.75%
23,178 $1.45 Million
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $58,578 - $68,616
990 Added 4.68%
22,126 $1.31 Million
Q2 2021

Aug 10, 2021

BUY
$61.91 - $67.42 $128,648 - $140,098
2,078 Added 10.9%
21,136 $1.41 Million
Q1 2021

Apr 30, 2021

SELL
$59.34 - $66.74 $478,458 - $538,124
-8,063 Reduced 29.73%
19,058 $1.2 Million
Q4 2020

Jan 25, 2021

BUY
$57.74 - $65.43 $46,827 - $53,063
811 Added 3.08%
27,121 $1.68 Million
Q3 2020

Nov 12, 2020

SELL
$57.43 - $63.64 $1.17 Million - $1.29 Million
-20,292 Reduced 43.54%
26,310 $1.59 Million
Q2 2020

Aug 13, 2020

BUY
$54.82 - $64.09 $765,835 - $895,337
13,970 Added 42.81%
46,602 $2.74 Million
Q1 2020

Apr 21, 2020

SELL
$46.4 - $67.43 $27,654 - $40,188
-596 Reduced 1.79%
32,632 $1.82 Million
Q4 2019

Feb 12, 2020

BUY
$49.21 - $64.19 $562,814 - $734,141
11,437 Added 52.48%
33,228 $2.13 Million
Q3 2019

Nov 12, 2019

BUY
$42.77 - $50.71 $26,859 - $31,845
628 Added 2.97%
21,791 $1.11 Million
Q2 2019

Aug 15, 2019

BUY
$44.62 - $49.34 $909,623 - $1.01 Million
20,386 Added 2623.68%
21,163 $960,000
Q1 2019

Jul 01, 2019

SELL
$45.12 - $53.8 $699,901 - $834,545
-15,512 Reduced 95.23%
777 $16.3 Million
Q1 2019

May 13, 2019

BUY
$45.12 - $53.8 $707,887 - $844,068
15,689 Added 2614.83%
16,289 $777,000
Q4 2018

Feb 12, 2019

BUY
$48.76 - $63.23 $28,768 - $37,305
590 Added 5900.0%
600 $12,000
Q3 2018

Nov 05, 2018

SELL
$55.19 - $62.25 $1.01 Million - $1.14 Million
-18,313 Reduced 99.95%
10 $595,000
Q2 2018

Aug 15, 2018

BUY
$50.53 - $62.98 $668,410 - $833,099
13,228 Added 259.63%
18,323 $1.01 Million
Q1 2018

May 07, 2018

BUY
$59.92 - $68.98 $13,242 - $15,244
221 Added 4.53%
5,095 $322,000
Q4 2017

Feb 09, 2018

BUY
$59.94 - $65.35 $292,147 - $318,515
4,874
4,874 $299,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $86B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Centaurus Financial, Inc. Portfolio

Follow Centaurus Financial, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Centaurus Financial, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Centaurus Financial, Inc. with notifications on news.